SAB 183
Alternative Names: SAB-183Latest Information Update: 25 Jun 2024
At a glance
- Originator SAB Biotherapeutics
- Developer SAB BIO; United States Army Medical Research Institute of Infectious Diseases
- Class Antibacterials; Polyclonal antibodies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Plague